Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Oncology · FDA Approved

Histrelin (Vantas)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

Histrelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH) that functions as a GnRH agonist. It is delivered by a subcutaneous hydrogel implant designed for continuous release over about 12 months, producing initial gonadotropin stimulation followed by sustained pituitary downregulation and suppression of sex steroid production (PMID 16515997).

The Vantas implant for palliative treatment of advanced prostate cancer has been discontinued in the US, while the Supprelin LA implant for central precocious puberty remains marketed. Its structure carries a benzyl-protected D-histidine at position 6 and a C-terminal ethylamide in place of glycine 10, which increase receptor potency and resistance to degradation.

02 · Research summary & key findings

The once-yearly Vantas implant was approved for advanced prostate cancer (PMID 20735905), with FDA records listing approval in 2004, and a separate once-yearly histrelin implant was approved for central precocious puberty in 2007 (PMID 19920916). In the pivotal open-label study of the 50 mg implant in 134 evaluable men with advanced prostate cancer, all reached castrate testosterone by week 4 and more than 99% maintained suppression through week 52 (PMID 16515997). In an extension study, testosterone stayed below 50 ng/dL with repeated yearly implants for up to 4 years, and hot flashes were the most common drug-related adverse event (PMID 21851539).

03 · Regulatory status

Histrelin (Vantas) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Histrelin (Vantas) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Subcutaneous implant

References

  1. [1]Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer J Urol, 2006. PMID 16515997
  2. [2]Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty Drug Des Devel Ther, 2009. PMID 19920916
  3. [3]Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer Can J Urol, 2010. PMID 20735905
  4. [4]Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer BJU Int, 2012. PMID 21851539

Primary literature

Related peptides in Oncology

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.